Dr. Bensinger - ASH 2008 - A Phase II Study of Bortezomib (Velcade®), Cyclophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma.
William Bensinger, MD Fred Hutchinson Cancer Research Center Seattle, Washington U.S.A. Member, IMF Board of Scientific Advisors
12.27.08
To view the video full screen, click on the small
button next to the volume control in the
lower right hand corner.
back
button next to the volume control in the
lower right hand corner.
print
related articles